# PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

> **NCT01131247** · PHASE2 · WITHDRAWN · sponsor: **Nevada Cancer Institute** · enrollment: 37 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **DRUG:** ofatumumab + bendamustine

## Key facts

- **NCT ID:** NCT01131247
- **Lead sponsor:** Nevada Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 37 (ESTIMATED)
- **Why stopped:** PI left institution
- **Last updated:** 2011-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131247, "PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01131247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*